Display options
Cite
Zhu Z, Schnell L, Müller B, et al. The Antibiotic Bacitracin Protects Human Intestinal Epithelial Cells and Stem Cell-Derived Intestinal Organoids from . Stem Cells Int. 2019;2019:4149762doi: 10.1155/2019/4149762.
Zhu, Z., Schnell, L., Müller, B., Müller, M., Papatheodorou, P., & Barth, H. (2019). The Antibiotic Bacitracin Protects Human Intestinal Epithelial Cells and Stem Cell-Derived Intestinal Organoids from . Stem cells international, 20194149762. https://doi.org/10.1155/2019/4149762
Zhu, Ziyu, et al. "The Antibiotic Bacitracin Protects Human Intestinal Epithelial Cells and Stem Cell-Derived Intestinal Organoids from ." Stem cells international vol. 2019 (2019): 4149762. doi: https://doi.org/10.1155/2019/4149762
Zhu Z, Schnell L, Müller B, Müller M, Papatheodorou P, Barth H. The Antibiotic Bacitracin Protects Human Intestinal Epithelial Cells and Stem Cell-Derived Intestinal Organoids from . Stem Cells Int. 2019 Aug 05;2019:4149762. doi: 10.1155/2019/4149762. eCollection 2019. PMID: 31467562; PMCID: PMC6701344.
Copy Download .nbib Format: NLM
Share it on

Stem Cells Int. 2019 Aug 05;2019:4149762. doi: 10.1155/2019/4149762. eCollection 2019.

The Antibiotic Bacitracin Protects Human Intestinal Epithelial Cells and Stem Cell-Derived Intestinal Organoids from .

Stem cells international

Ziyu Zhu, Leonie Schnell, Bastian Müller, Martin Müller, Panagiotis Papatheodorou, Holger Barth

Affiliations

  1. Institute of Pharmacology and Toxicology, University of Ulm Medical Center, 89081 Ulm, Germany.
  2. Department of Internal Medicine I, University of Ulm Medical Center, 89081 Ulm, Germany.

PMID: 31467562 PMCID: PMC6701344 DOI: 10.1155/2019/4149762

Abstract

Bacitracin is an established antibiotic for local application and inhibits the cell wall synthesis of Gram-positive bacteria. Recently, we discovered a completely different mode of action of bacitracin and reported that this drug protects human cells from intoxication by a variety of medically relevant bacterial protein toxins including CDT, the binary actin ADP-ribosylating toxin of

Conflict of interest statement

The authors declare that there are no conflicts of interest.

References

  1. J Inorg Biochem. 2002 Jul 25;91(1):46-58 - PubMed
  2. J Biol Chem. 2003 Nov 7;278(45):44535-41 - PubMed
  3. Rev Physiol Biochem Pharmacol. 2004;152:23-47 - PubMed
  4. Nature. 2007 Mar 22;446(7134):415-9 - PubMed
  5. Clin Infect Dis. 2008 Jan 15;46 Suppl 1:S12-8 - PubMed
  6. Trends Microbiol. 2008 May;16(5):222-9 - PubMed
  7. N Engl J Med. 2008 Oct 30;359(18):1932-40 - PubMed
  8. Nat Rev Microbiol. 2009 Jul;7(7):526-36 - PubMed
  9. FEBS Lett. 2009 Oct 6;583(19):3133-9 - PubMed
  10. FEBS J. 2010 Jun;277(11):2454-62 - PubMed
  11. PLoS One. 2010 May 17;5(5):e10673 - PubMed
  12. Nature. 2010 Oct 7;467(7316):711-3 - PubMed
  13. FEBS J. 2011 Jun;278(12):2034-43 - PubMed
  14. J Infect Dis. 2012 Feb 1;205(3):384-91 - PubMed
  15. Clin Infect Dis. 2013 Jun;56(11):1589-600 - PubMed
  16. Gut Microbes. 2014 Jan-Feb;5(1):15-27 - PubMed
  17. N Engl J Med. 2015 Jul 16;373(3):287-8 - PubMed
  18. Z Gastroenterol. 2016 Aug;54(8):748-59 - PubMed
  19. Gut. 2017 Mar;66(3):473-486 - PubMed
  20. Sci Rep. 2017 Jun 2;7(1):2724 - PubMed
  21. Adv Exp Med Biol. 2018;1050:77-96 - PubMed
  22. J Infect Dis. 2018 Sep 22;218(9):1424-1435 - PubMed
  23. Per Med. 2018 Nov;15(6):461-465 - PubMed
  24. FASEB J. 2019 Apr;33(4):5755-5771 - PubMed
  25. Infect Immun. 1988 Sep;56(9):2299-306 - PubMed
  26. Arch Intern Med. 1986 Jun;146(6):1101-4 - PubMed
  27. J Antibiot (Tokyo). 1995 Mar;48(3):233-42 - PubMed
  28. Nature. 1995 Jun 8;375(6531):500-3 - PubMed

Publication Types